Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
- Conditions
- Warts
- Registration Number
- NCT00116675
- Lead Sponsor
- Graceway Pharmaceuticals, LLC
- Brief Summary
The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks.
A second purpose is to evaluate the safety of the drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 84
- Diagnosis of common warts
- Ages between 3 to 11
- Other types of wart(s), ie. plantar
- Currently participating in another clinical study
- Chronic viral hepatitis B or C
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Clearance of treated wart(s)
- Secondary Outcome Measures
Name Time Method Partial clearance of treated wart(s) Wart recurrence
Trial Locations
- Locations (10)
Longmont Clinic/Longmont Medical Research Network
🇺🇸Longmont, Colorado, United States
Mercy Health Research
🇺🇸St. Louis, Missouri, United States
Walla Walla Clinic
🇺🇸Walla Walla, Washington, United States
Rhode Island Hospital - Jane Brown Building
🇺🇸Providence, Rhode Island, United States
Children's Clinic of Jonesboro, PA
🇺🇸Jonesboro, Arkansas, United States
Alpine Pediatrics
🇺🇸Pleasant Grove, Utah, United States
Advanced Healthcare
🇺🇸Milwaukee, Wisconsin, United States
DermResearch, Inc.
🇺🇸Austin, Texas, United States
University of California - San Francisco
🇺🇸San Francisco, California, United States
Dartmouth-Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States